Skip to main content
Home / Current Drug Therapy, Volume 7, Number 4
Current Drug Therapy publishes frontier reviews on all the latest advances in drug therapy. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: new and existing drugs, therapies and medical devices.

The journal is essential reading for all researchers and clinicians involved in drug therapy.

Publisher: Bentham Science Publishers

More about this publication?
Volume 7, Number 4, 2012

Articles

Open Access Applicability and Approaches of (Meth) Acrylate Copolymers (Eudragits) in Novel Drug Delivery Systems
pp. 219-234(16)
Authors: Animesh, Kumar; Afrasim, Moin; R. Bommareddy, Rami; Ayaz, Ahmed; Shruthi, Ravi; G. Shivakumar, Hoskote

Favourites:
ADD

Open Access Current Concepts on the Management of Chordoma
pp. 235-247(13)
Authors: Amichetti, Maurizio; Amelio, Dante; Rombi, Barbara; Vennarini, Sabina; Cianchetti, Marco

Favourites:
ADD

Open Access Anti-Inflammatory Drug Targeting in Asthma. Should Inhaled Corticosteroids Reach the Small Airways?
pp. 248-254(7)
Author: N. Richard Dekhuijzen, P.

Favourites:
ADD

Open Access Approaches to Stabilize Amorphous Form - A Review
pp. 255-262(8)
Authors: R. Jadhav, Kisan; S. Pacharane, Sharad; P. Pednekar, Priti; V. Koshy, Praveen; J. Kadam, Vilasrao

Favourites:
ADD

Open Access Renal Biopsy Research with Implications for Therapy of Glomerulonephritis
pp. 263-267(5)
Author: V. Jargin, Sergei

Favourites:
ADD

Open Access Ca2+ Signalling in Damaged Endothelium and Arterial Remodelling: Do Connexin Hemichannels Provide a Suitable Target to Prevent In-stent Restenosis?
pp. 268-280(13)
Authors: Moccia, Francesco; Berra-Romani, Roberto; Tanzi, Franco

Favourites:
ADD

Open Access Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
pp. 281-289(9)
Authors: R. Chuda, Ravindra; Vishnu, Prakash; Aboulafia, David

Favourites:
ADD

Open Access Acknowledgements To The Reviewers
pp. 290-290(1)

Favourites:
ADD

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content